eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

News

Inquiries

31 March

2022

Summary of 2021

Pure Biologics has published its annual report for 2021 in which it summarizes its financial results and scientific achievements.

Project PB004 – start of the in vivo studies

28 March

2022

Project PB004 – start of the in vivo studies

Pure Biologics has signed a research agreement with The Jackson Laboratory, a leading US animal research services company operating worldwide, to launch the first in vivo preclinical pilot study in the PB004 project.

Pure Biologics becomes a partner of the Warsaw Health Innovation Hub

16 February

2022

Pure Biologics becomes a partner of the Warsaw Health Innovation Hub

February 15, 2022 Pure Biologics S.A. joined as a partner to the Warsaw Health Innovation Hub initiative, being under the aegis of the Medical Research Agency.